세계의 복막투석 시장 : 제품별, 양식별, 적응증별, 적응증 질환별, 최종 사용자별, 지역별 - 예측(-2029년)

The peritoneal dialysis market is projected to reach USD 12.70 Billion by 2029 from USD 9.58 Billion in 2024 at a CAGR of 5.8% during the forecast period. Favorable healthcare policies in developed markets have highly increased access to peritoneal dialysis since many now offer reimbursements for home-based dialysis treatments. In most cases, the United States, Canada, and several others in Europe have come up with policies that acknowledge the cost-effectiveness and better benefits for patients through peritoneal dialysis over in-center hemodialysis. Such policies reduce the barriers associated with the cost of treatment by establishing reimbursement coverage for a significant portion of the PD-associated treatment costs. This could make PD a much more affordable and accessible form of therapy for patients, and reimbursement programs promote the practice of healthcare providers to recommend PD due to its flexibility and practicality, also for those preferring home management of treatment. For instance, in the United States, Medicare's ESRD program encourages wider adoption by providing reimbursements for home dialysis. Likewise, other developed markets also are following and encouraging home dialysis since it reduces hospital admissions, improves patient outcomes, and reduces burdens on the healthcare facilities. The financial support that comes with PD has become a reason for the aged and bedridden patients who have been able to live better as a result of reduced immobilization and enhanced personal care.

"The peritoneal solution bags segment is accounted for the largest share of peritoneal dialysis market."

Peritoneal dialysis solution bags are less expensive than machines because they are not reliant upon pricey technology and maintenance. Because of this, these bags are very inexpensive for patients and healthcare systems, whose production and distribution costs make it possible to sell these bags at prices within everyone's reach, especially in countries that have tightly constrained health care budgets. Solution bags also reduce the requirement for costly equipment and training of the staff, thereby reducing the overall cost of treatment. This adds to the attractiveness of solution bags as a treatment option for a larger number of patients in resource-poor settings for access to necessary dialysis.

"Continuous Ambulatory Peritoneal Dialysis (CAPD) segment holds the largest market share of peritoneal dialysis market."

The increased coverage of CAPD supplies, especially the solution bags, has stimulated its adoption, especially in developing countries. CAPD, being any form of dialysis treatment, requires only basic supplies, like solution bags, and hence is much simpler to distribute and implement in areas with very poor healthcare resources than expensive machinery. Therefore, it is more cost-effective and accessible to patients in low-resource settings as a practically offered form of dialysis. Ease of use and minimization of the use of hospital facilities further increase the adoption rate of CAPD, thereby increasing access to dialysis care in underprivileged areas globally.

"End-stage renal disease segment holds the largest market share in the global peritoneal dialysis market and expected to grow at the highest CAGR during the forecast period"

Most healthcare systems promote home dialysis options to decrease the prevalence of hospital visits attributed to end-stage renal disease (ESRD), which subsequently saves the overall cost of healthcare. Health care providers would benefit from home peritoneal dialysis by reducing the need for in-center dialysis, thus saving hospital facility capacities and minimizing the problems it poses both to facilities and personnel. Home dialysis will also improve patients' lives as they assume control over their treatment. An added advantage of home-based PD is that it is very economical since it saves transportation costs, it minimizes the susceptibility to infection, and encourages continuity of care, which makes it an attractive modality for health care systems.

"Home care setttings segment accounted for the largest market share in the global peritoneal dialysis market and expected to grow at the highest CAGR during the forecast period."

Portable and user-friendly dialysis equipment have further improved the safety and ease of treatment in the home setting for patients. Modern peritoneal dialysis machines are well designed with intuitive interfaces, automation, and compact size, making them devices that patients can use with relative ease, without relying so much on medical knowledge. Thus, independent and comfortable home-based dialysis has reduced a patient's dependence on healthcare professionals. Safety measures have upgraded with live monitoring and automatic alarms that enhanced outcomes best dealt with early before dangers occur. In those innovations, patient confidence in handling their care improved, while the treatment compliance was generally enhanced.

"North America to witness the substantial growth rate during the forecast period."

The peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the peritoneal dialysis market in 2023. North America is the largest regional market for global peritoneal dialysis, and this is partly because healthcare providers in this region have been trained specifically to manage this treatment. This places them in a better position to ensure that patients requiring the treatment receive a holistic education on how to carry out procedures safely and effectively at home. Moreover, these professionals provide timely interventions through effective monitoring, thus making the outcomes better as well as complications as low as possible. Specialized training programs and ongoing professional development in the region further underpin quality care. Such professionalism among healthcare professionals has indeed contributed to success in the introduction and spread of peritoneal dialysis in North America.

A breakdown of the primary participants (supply-side) for the peritoneal dialysis market referred to for this report is provided below:

• By Company Type: Tier 1-45%, Tier 2-30%, and Tier 3-25%
• By Designation: C-level-35%, Director Level-25%, and Others-40%
• By Region: North America-40%, Europe-20%, Asia Pacific-25%, Latin America- 10%, and Middle East and Africa- 3% and GCC Countries- 2%

Prominent players in this market include Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), AMECATH (Egypt), Polymedicure (India), Huaren Pharmaceutical (China), AWAK Technologies (Singapore), Innovative Renal Care (US), Romsons (India), SSEM Mthembu Medical (Pty) Ltd (South Africa), Renax Biomedical Technology Co., Ltd (China), and Advin Health Care (India).

Research Coverage:

The market study covers the peritoneal dialysis market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by offering, modality, disease indication, end user and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of Market Dynamics: Drivers (rising prevalence of chronic kidney diseases, growing prevalence of diabetes and hypertension, and technological advancements and increased investment in R&D) restraints (underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)) opportunities (increasing growth opportunities in emerging economies, and surge in demand for home dialysis treatment), and challenges (growing incidence of treated kidney failure, and shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs))
• Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the peritoneal dialysis market.
• Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the peritoneal dialysis market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the peritoneal dialysis market like Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 IMPACT OF AI/GEN AI

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
  • 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.3 USAGE-BASED MARKET ESTIMATION
  • 2.2.4 PRIMARY RESEARCH VALIDATION
• 2.3 GROWTH FORECAST ESTIMATION
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PERITONEAL DIALYSIS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING (2023)
• 4.3 PERITONEAL DIALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 REGIONAL MIX: PERITONEAL DIALYSIS MARKET (2024-2029)
• 4.5 PERITONEAL DIALYSIS MARKET: DEVELOPED VS. DEVELOPING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of chronic kidney diseases
    • 5.2.1.2 Growing prevalence of diabetes and hypertension
    • 5.2.1.3 Technological advancements and increased investment in R&D
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing growth opportunities in emerging economies
    • 5.2.3.2 Surge in demand for home dialysis treatment
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs)
    • 5.2.4.2 High risk of peritonitis as a barrier to peritoneal dialysis adoption
• 5.3 INDUSTRY TRENDS
  • 5.3.1 INCREASED ADOPTION OF HOME-BASED TREATMENTS
  • 5.3.2 RISING INCIDENCE OF CHRONIC KIDNEY DISEASE (CKD)
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Automated peritoneal dialysis (APD) machines
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Remote monitoring systems
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Wearable technology
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR PERITONEAL DIALYSIS MACHINES, SOLUTION BAGS, CATHETERS, AND TRANSFER SETS (HS CODE 9018)
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF SUPPLIERS
  • 5.8.4 BARGAINING POWER OF BUYERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 REGULATORY ANALYSIS
  • 5.9.1 REGULATORY LANDSCAPE
    • 5.9.1.1 North America
      • 5.9.1.1.1 US
      • 5.9.1.1.2 Canada
    • 5.9.1.2 Europe
    • 5.9.1.3 Asia Pacific
      • 5.9.1.3.1 India
      • 5.9.1.3.2 China
      • 5.9.1.3.3 Japan
      • 5.9.1.3.4 South Korea
    • 5.9.1.4 Latin America
      • 5.9.1.4.1 Brazil
      • 5.9.1.4.2 Mexico
    • 5.9.1.5 Middle East
    • 5.9.1.6 Africa
  • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 PATENT ANALYSIS
  • 5.10.1 PATENT PUBLICATION TRENDS FOR PERITONEAL DIALYSIS MARKET
  • 5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER (2023)
• 5.12 KEY CONFERENCES & EVENTS, 2024-2025
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA
• 5.14 ECOSYSTEM ANALYSIS
• 5.15 ADJACENT MARKET ANALYSIS
  • 5.15.1 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET
  • 5.15.2 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
• 5.16 CASE STUDY ANALYSIS
• 5.17 IMPACT OF GENERATIVE AI ON PERITONEAL DIALYSIS MARKET
• 5.18 UNMET NEEDS AND END-USER EXPECTATIONS
• 5.19 TRENDS/DISRUPTIONS AFFECTING CUSTOMERS' BUSINESSES
• 5.20 INVESTMENT & FUNDING SCENARIO
• 5.21 PROCEDURE DATA ANALYSIS
  • 5.21.1 PREVALENCE DATA FOR TREATED KIDNEY FAILURE

6 PERITONEAL DIALYSIS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PERITONEAL DIALYSIS PRODUCTS
  • 6.2.1 PERITONEAL DIALYSIS SOLUTION BAGS
    • 6.2.1.1 High demand for solutions to boost segmental growth
  • 6.2.2 PERITONEAL DIALYSIS MACHINES
    • 6.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption
  • 6.2.3 PERITONEAL DIALYSIS CATHETERS
    • 6.2.3.1 Favorable reimbursement policies to support market growth
  • 6.2.4 PERITONEAL DIALYSIS TRANSFER SETS
    • 6.2.4.1 Product recalls to limit market growth
  • 6.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS
• 6.3 PERITONEAL DIALYSIS SERVICES
  • 6.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET

7 PERITONEAL DIALYSIS MARKET, BY MODALITY

• 7.1 INTRODUCTION
• 7.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)
  • 7.2.1 SUPERIOR CLEARANCE OF HIGH-MOLECULAR-WEIGHT SUBSTANCES TO DRIVE MARKET
• 7.3 AUTOMATED PERITONEAL DIALYSIS (APD)
  • 7.3.1 RISK OF RAPID DECLINE IN RESIDUAL RENAL FUNCTIONS TO LIMIT ADOPTION

8 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION

• 8.1 INTRODUCTION
• 8.2 END-STAGE RENAL DISEASE
  • 8.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
• 8.3 ACUTE KIDNEY INJURY
  • 8.3.1 INCREASING HOSPITALIZATIONS TO PROPEL MARKET GROWTH
• 8.4 OTHER DISEASES

9 PERITONEAL DIALYSIS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOME CARE SETTINGS
  • 9.2.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH
• 9.3 HOSPITALS & INDEPENDENT DIALYSIS CENTERS
  • 9.3.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET
• 9.4 OTHER END USERS

10 PERITONEAL DIALYSIS MARKET, BY REGION

• 10.1 INTRODUCTION
  • 10.1.1 PERITONEAL DIALYSIS PREVALENCE DATA
  • 10.1.2 PERITONEAL DIALYSIS PROCEDURE DATA
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 US to account for largest market share during study period
  • 10.2.3 CANADA
    • 10.2.3.1 Shortage of dialysis facilities and increased treatment cost to limit market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Rising number of end-stage renal disease (ESRD) patients to boost market growth
  • 10.3.3 UK
    • 10.3.3.1 Increased number of new dialysis centers and technological advancements to support market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Low cost of peritoneal dialysis and consistent reimbursement policies to drive market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Increasing research activities and growing patient population with acute renal failure to augment market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Favorable reimbursement scenario to boost market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 High prevalence of end-stage renal disease (ESRD) and large geriatric population to support market growth
  • 10.4.3 CHINA
    • 10.4.3.1 Increasing prevalence of diabetes and hypertension to drive market
  • 10.4.4 INDIA
    • 10.4.4.1 Favorable government initiatives and high prevalence of kidney disease to fuel market growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Increasing government initiatives about renal care to support market growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Growing geriatric population with chronic kidney disease to propel market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Brazil to account for largest share of Latin American market during forecast period
  • 10.5.3 MEXICO
    • 10.5.3.1 Increasing patient population and growing middle class population to boost market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 GROWING DEMAND FOR CONVENIENT AND ACCESSIBLE RENAL CARE TO PROPEL GROWTH
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 10.7 GCC COUNTRIES
  • 10.7.1 HIGHER DISPOSABLE INCOME AND INCREASED GOVERNMENT HEALTHCARE EXPENDITURE TO PROPEL MARKET GROWTH
  • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PERITONEAL DIALYSIS MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Offering footprint
    • 11.5.5.3 Modality footprint
    • 11.5.5.4 Disease indication footprint
    • 11.5.5.5 End-user footprint
    • 11.5.5.6 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
• 11.8 COMPETITIVE SCENARIO
  • 11.8.1 PRODUCT APPROVALS
  • 11.8.2 DEALS
  • 11.8.3 EXPANSIONS
• 11.9 BRAND/PRODUCT COMPARISON
• 11.10 PERITONEAL DIALYSIS MARKET: R&D EXPENDITURE

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 FRESENIUS MEDICAL CARE AG
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products & services offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 BAXTER INTERNATIONAL INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products & services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 MEDTRONIC PLC
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products & services offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 DAVITA INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products & services offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Deals
      • 12.1.4.3.2 Expansions
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 BECTON, DICKINSON AND COMPANY
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products & services offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Expansions
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 TERUMO CORPORATION
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products & services offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product approvals
      • 12.1.6.3.2 Deals
      • 12.1.6.3.3 Expansions
  • 12.1.7 UTAH MEDICAL PRODUCTS, INC.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products & services offered
  • 12.1.8 DIAVERUM AB
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products & services offered
  • 12.1.9 MEDIONICS
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products & services offered
  • 12.1.10 NEWSOL TECHNOLOGIES INC.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products & services offered
  • 12.1.11 APOLLO DIALYSIS PVT. LTD.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products & services offered
  • 12.1.12 U.S. RENAL CARE, INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products & services offered
  • 12.1.13 NORTHWEST KIDNEY CENTERS
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products & services offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Deals
      • 12.1.13.3.2 Expansions
  • 12.1.14 RELAVO
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products & services offered
  • 12.1.15 MITRA INDUSTRIES PVT. LTD.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products & services offered
• 12.2 OTHER PLAYERS
  • 12.2.1 JMS CO., LTD.
  • 12.2.2 AMECATH
  • 12.2.3 POLYMEDICURE
  • 12.2.4 HUAREN PHARMACEUTICAL
  • 12.2.5 AWAK TECHNOLOGIES
  • 12.2.6 INNOVATIVE RENAL CARE
  • 12.2.7 ROMSONS
  • 12.2.8 SSEM MTHEMBU MEDICAL (PTY) LTD.
  • 12.2.9 RENAX BIOMEDICAL TECHNOLOGY CO., LTD.
  • 12.2.10 ADVIN HEALTH CARE

13 APPENDIX

• 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.2 CUSTOMIZATION OPTIONS
• 13.3 RELATED REPORTS
• 13.4 AUTHOR DETAILS